Between October 18–21, this website will move to a new web address (from health.gov to odphp.health.gov). During that time, some functions might not work as expected. We appreciate your patience and understanding as we’re working to make this transition as smooth as possible.

U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate

About this resource:

Non-Systematic Review

Source: Centers for Disease Control and Prevention

Last Reviewed: May 2021

Workgroups: Family Planning Workgroup

In this update to the U.S. Selected Practice Recommendations for Contraceptive Use, the Centers for Disease Control and Prevention (CDC) recommends making self-administered subcutaneous depot medroxyprogesterone acetate (DMPA-SC) available as an additional approach to deliver injectable contraception.

DMPA-SC is a method of birth control that is given under the skin, usually every 3 months. CDC found that self-administered DMPA-SC might improve access to contraception by removing barriers, like in-person visits to a health care provider, while promoting empowerment through self-care.

Read more about this resource

Objectives related to this resource (2)

Increase the proportion of women at risk for unintended pregnancy who use effective birth control — FP‑10
Little or no detectable change
Increase the proportion of adolescent females at risk for unintended pregnancy who use effective birth control — FP‑11
Little or no detectable change

Suggested Citation

1.

Curtis KM, Nguyen A, Reeves JA, Clark EA, Folger SG, Whiteman MK. (2021). Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate. Retrieved from https://www.cdc.gov/mmwr/volumes/70/wr/mm7020a2.htm?s_cid=mm7020a2_w.